Delivery Order SPE2DB25D9320-SPE2DB25FWFCS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc. on September 3, 2025, for the supply of Xtandi 40 mg capsules (120-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this order for delivery to Park Ridge, IL. The contract utilizes a firm fixed-price structure with an ultimate completion date of September 4, 2025, and no set-aside designation...
- The Defense Logistics Agency awarded a delivery order valued at $8,622.72 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, carries no set-aside designation. The award is issued under DMS Pharmaceutical Group's existing single-award Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,934.05 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The contract, effective August 12, 2025 with completion by August 13, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. This award represents a single transaction under DMS Pharmaceutical Group's larger...
- On September 8, 2025, the Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The contract, valued at $8,622.72, carries a firm fixed-price structure with an ultimate completion date of September 9, 2025. The delivery order carries no set-aside designation and represents performance at the contractor's...
- The Defense Logistics Agency awarded a delivery order valued at $25,868.10 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, issued on August 19, 2025, with an ultimate completion date of August 20, 2025, represents a product delivery under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA. The contract carries no set-aside designation, allowing the woman-owned small business to compete on an...
- The Defense Logistics Agency awarded a $4,311.35 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on August 29, 2025, for the supply of Xtandi 40 mg capsules (120-count units). This award carries an ultimate completion date of September 2, 2025, and represents a standard delivery order issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA. The contract contains no set-aside designation, allowing the woman-owned small business to compete directly...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $50,885.64 to DMS Pharmaceutical Group Inc. on September 10, 2025, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price contract is classified as a delivery order with an ultimate completion date of September 11, 2025, and carries no set-aside designation. The work will be performed in Park Ridge, Illinois, where DMS Pharmaceutical Group maintains its headquarters as a woman-owned small business...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, awarded on September 3, 2025, with an ultimate completion date of September 4, 2025, was issued without a set-aside designation. The award represents a single delivery order issued under DMS...
- The Defense Logistics Agency awarded a delivery order valued at $12,934.05 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (quantity: 120). This firm fixed-price delivery order, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, represents a continuation of the ongoing pharmaceutical supply relationship between the agency and the vendor. The award carries no...
- The Defense Logistics Agency issued a firm fixed-price delivery order valued at $12,792.31 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 40 mg capsules (120-count units). DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its Park Ridge location with completion expected by July 24, 2025. This delivery order was awarded without a set-aside designation, allowing the vendor to compete in the open...
- SPE2DB25D9320Indefinite Delivery Contract
- SPE2DB25D9320-SPE2DB25FWFCSDelivery Order
The Defense Logistics Agency awarded a $8,622.72 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on September 8, 2025, for the supply of Xtandi 40 mg capsules (quantity: 120 units). The contract, which is set to be completed by September 9, 2025, represents a discrete delivery against DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA. This delivery order carries no set-aside designation and will be performed at the contractor's facility in Park Ridge, Illinois. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler that serves as a critical supplier within the federal pharmaceutical supply chain, particularly for the Department of Defense healthcare system. The company holds a significant single-award IDC with DLA valued at $499,999,999 through November 2026 under the SPE2DB program, which authorizes firm fixed-price delivery orders for an extensive portfolio of branded and generic prescription drugs, biologics, and medical consumables. This award of Xtandi—a prescription medication used in oncology treatment—exemplifies the company's core business of distributing specialized pharmaceutical products to military health facilities nationwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.6k | 9/8/25 |